Medicament for preventing and/or treating dry eye
US-11331322-B1 · May 17, 2022 · US
Medicament for preventing and/or treating dry eye
US12005063B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12005063-B2 |
| Application number | US-202217722947-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2022 |
| Priority date | Sep 15, 2021 |
| Publication date | Jun 11, 2024 |
| Grant date | Jun 11, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol hydrochloride to the subject. 2. The method according to claim 1 , wherein the dry eye accompanies corneal and conjunctival epithelium disorder caused by at least one selected from the group consisting of superficial punctate keratopathy, corneal epithelium defect, corneal erosion, corneal ulcer, conjunctival epithelium defect, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, non-infectious keratitis, and non-infectious conjunctivitis. 3. The method according to claim 1 , wherein the dry eye is a disease caused by at least one selected from the group consisting of tear film instability, lacrimal hyposecretion, xerophthalmia, tear deficiency, keratoconjunctivitis sicca, lacrimal gland dysfunction, meibomian gland dysfunction, VDT (Visual Display Terminal) operation, use of contact lenses, tear abnormalities, and keratoconjunctivitis. 4. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.1% (w/v) or less. 5. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.01% (w/v) or less. 6. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.1% (w/v). 7. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.01% (w/v). 8. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.005% (w/v). 9. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.001% (w/v). 10. The method according to claim 1 , wherein the olodaterol hydrochloride is administered in the form of an eye drop. 11. The method according to claim 1 , wherein administering the olodaterol hydrochloride does not substantially increase and/or reduce intraocular pressure.
Assignees
Inventors
Classifications
Ophthalmic agents · CPC title
- A61K31/538Primary
ortho- or peri-condensed with carbocyclic ring systems · CPC title
Artificial tears; Irrigation solutions · CPC title
- A61K31/536Primary
ortho- or peri-condensed with carbocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12005063B2 cover?
- A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is als…
- Who is the assignee on this patent?
- Santen Pharmaceutical Co Ltd, Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification A61K31/538. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).